EGFR and non-small cell lung carcinoma: In the 2019-guideline v3, the National Comprehensive Cancer Network indicates that genes, including EGFR, ALK, BRAF, KRAS, HER2, ROS1, RET, and MET, are therapeutic targets for treating NSCLC.